SynthesisJournal of lower genital tract disease2020
Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review.
Synthesis in Journal of lower genital tract disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Human papillomavirus (HPV) infection and prevalence of colorectal cancer: an updated systematic review and meta-analysis of global data.International journal of surgery (London, England) · 2026Pooled it
- Low Rates of Dual-Site and Concordant Oral-Cervical Human Papillomavirus Infections and Cancers: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Article
- Improving cervical screening risk stratification through extended human papillomavirus genotyping and age-specific data.European journal of public health · 2026Article
- Health care policy trial of primary human papillomavirus-based cervical screening in Denmark: Comparison of three triage algorithms.International journal of cancer · 2026Article
- Observational
- Long-term human papillomavirus genotype-specific risk of cervical high-grade intraepithelial lesion and cancer-By age group and triage cytology.International journal of cancer · 2026Article
- High-risk and low-risk human papillomavirus detection in self-collected samples compared to clinician-collected samples in a Polish population.Frontiers in public health · 2026Article
- CINPred: a risk prediction tool for cervical intraepithelial neoplasia.Frontiers in oncology · 2026Article
- [Cervical cancer screening in Germany 2020-2022 : An analysis of the first round of screening according to the specifications of the oKFE-RL].Pathologie (Heidelberg, Germany) · 2026Article
- Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.International journal of cancer · 2026Article
- Article
- Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 study.Infectious agents and cancer · 2025Article
- Contemporary Status and Frontiers of Cervical Cancer Screening in the United States.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- Predictive Factors for Cervical Intraepithelial Neoplasia in Women with Abnormal Cytology According to Human Papillomavirus Genotype: An Observational Study.International journal of molecular sciences · 2025Observational
- Human Papillomavirus Genotyping and Viral Load as a Predictor of Cervical Lesions: A Prospective Study.Journal of medical virology · 2025Article
- Modelling the cost-effectiveness of cervical cancer screening with HPV self-sampling and molecular triage for women aged 60-69 years.Discover oncology · 2025Article
- Risk-Based Triage Strategy by Extended HPV Genotyping for Women With LSIL Cytology: A Real-World Study.Journal of medical virology · 2025Article
- Human papilloma virus (HPV) mediated cancers: an insightful update.Journal of translational medicine · 2025Review
- Development and validation of a multiplex qPCR method for identification of high-risk genotypes of human papillomavirus.Infectious agents and cancer · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThirteen human papillomavirus (HPV) genotypes are associated with the highest risk of cervical disease/cancer; however, the risk of disease progression and cancer is genotype dependent. The objective of this systematic review was to examine evidence for high-grade cervical intraepithelial neoplasia (≥CIN 3) risk discrimination using HPV genotyping. MATERIALS AND
methodsA systematic review of English and non-English articles through MEDLINE, Cochrane, clinicaltrials.gov, and abstracts presented at relevant professional society conferences were searched from 2000 to 2019. Search terms included: cervical cancer screening, HPV genotyping, CIN, HPV persistence, humans, and colposcopy; prospective, controlled trials, observational studies, and retrospective studies of residual specimens; evidence included HPV genotyping (beyond genotypes 16/18/45) results. Data were obtained independently by authors using predefined fields. Risk of bias was evaluated with a modified Newcastle-Ottawa Scale. The Grading of Recommendations, Assessment, Development and Evaluation methodology facilitated overall quality of evidence evaluation for risk estimation. The study protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42018091093). The primary outcome was CIN 3 or worse risk both at baseline and at different follow-up periods.
resultsOf 236 identified sources, 60 full texts were retrieved and 16 articles/sources were included. Risk of bias was deemed low; the overall quality of evidence for CIN 3 or worse risk with negative for intraepithelial lesions or malignancies or low-grade squamous intraepithelial cytology was assessed as moderate; that with atypical squamous cells-undetermined significance and "all cytology" was assessed as high. Clinical and methodological heterogeneity precluded meta-analysis. Human papillomavirus genotyping discriminated risk of CIN 3 or worse to a clinically significant degree, regardless of cytology result.
conclusionsThe evidence supports a clinical utility for HPV genotyping in risk discrimination during cervical cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.